The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...
Recursion Pharmaceuticals' recent momentum is hard to explain. The company could soar even more if it makes strong clinical progress. Despite its innovative approach, the biotech looks risky. It might ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback